RUNX1 and myeloid neoplasm: Therefore, AML with somatic RUNX1 variants is considered a biologically distinct AML subtype associated with poor outcomes in the 2016 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia [24].